BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dawood A, Abdul Basit S, Jayaraj M, Gish RG. Drugs in Development for Hepatitis B. Drugs 2017;77:1263-80. [PMID: 28660478 DOI: 10.1007/s40265-017-0769-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang G, Guan J, Khan NU, Li G, Shao J, Zhou Q, Xu L, Huang C, Deng J, Zhu H, Chen Z. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog 2021;13:22. [PMID: 33845868 DOI: 10.1186/s13099-021-00421-9] [Reference Citation Analysis]
2 Sun L, Zhang F, Guo F, Liu F, Kulsuptrakul J, Puschnik A, Gao M, Rijnbrand R, Sofia M, Block T, Zhou T. The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA. Antimicrob Agents Chemother 2020;65:e00640-20. [PMID: 33046485 DOI: 10.1128/AAC.00640-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ma A, Motyka B, Gutfreund K, Shi YE, George R. A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B. Hum Vaccin Immunother. 2020;16:756-778. [PMID: 31687879 DOI: 10.1080/21645515.2019.1689080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ma Z, Cao Q, Xiong Y, Zhang E, Lu M. Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. Vaccines (Basel) 2018;6:E6. [PMID: 29337856 DOI: 10.3390/vaccines6010006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
5 Seo HW, Seo JP, Cho Y, Ko E, Kim YJ, Jung G. Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly. Virus Research 2019;263:102-11. [DOI: 10.1016/j.virusres.2019.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Hou H, Kang Y, Zeng Y, Li Y, Shang J. Interleukin-7 augments CD8+ T cells function and promotes viral clearance in chronic hepatitis C virus infection. Cytokine 2018;102:26-33. [PMID: 29275010 DOI: 10.1016/j.cyto.2017.12.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
7 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
8 Song LT, Liu RR, Zhai HL, Meng YJ, Zhu M. Molecular mechanisms of tetrahydropyrrolo[1,2-c]pyrimidines as HBV capsid assembly inhibitors. Archives of Biochemistry and Biophysics 2019;663:1-10. [DOI: 10.1016/j.abb.2018.12.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
10 Nhu QM, Pockros PJ. Editorial: chronic hepatitis B combination therapy-emerging success as proof-of-concept for future hepatitis B eradication? Aliment Pharmacol Ther 2018;47:1560-1. [PMID: 29878430 DOI: 10.1111/apt.14680] [Reference Citation Analysis]
11 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
12 Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. Antimicrob Agents Chemother 2020;64:e01463-20. [PMID: 32868329 DOI: 10.1128/AAC.01463-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Nijampatnam B, Liotta DC. Recent advances in the development of HBV capsid assembly modulators. Current Opinion in Chemical Biology 2019;50:73-9. [DOI: 10.1016/j.cbpa.2019.02.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
14 Seo HW, Seo JP, Kim YJ, Jung G. WITHDRAWN: Cetylpyridinium chloride as a novel inhibitor of hepatitis B viral capsid assembly. Biochem Biophys Res Commun 2018:S0006-291X(18)30103-7. [PMID: 29353039 DOI: 10.1016/j.bbrc.2018.01.088] [Reference Citation Analysis]
15 Lee YH, Cha HM, Hwang JY, Park SY, Vishakantegowda AG, Imran A, Lee JY, Yi YS, Jun S, Kim GH, Kang HJ, Chung SJ, Kim M, Kim H, Han SB. Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. ACS Med Chem Lett 2021;12:242-8. [PMID: 33603970 DOI: 10.1021/acsmedchemlett.0c00606] [Reference Citation Analysis]
16 Yamasaki M, Matsuda N, Matoba K, Kondo S, Kanegae Y, Saito I, Nomoto A. Acetophenone 4-nitrophenylhydrazone inhibits Hepatitis B virus replication by modulating capsid assembly. Virus Res 2021;306:198565. [PMID: 34555437 DOI: 10.1016/j.virusres.2021.198565] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Seo HW, Seo JP, Jung G. Heat shock protein 70 and heat shock protein 90 synergistically increase hepatitis B viral capsid assembly. Biochem Biophys Res Commun 2018;503:2892-8. [PMID: 30115382 DOI: 10.1016/j.bbrc.2018.08.065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
18 Anderson RT, Lim SG, Mishra P, Josephson F, Donaldson E, Given B, Miller V. Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus. Gastroenterology 2019;156:529-533.e4. [DOI: 10.1053/j.gastro.2018.11.062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
19 Lin CT, Hsueh PR, Wu SJ, Yao M, Ko BS, Li CC, Hsu CA, Tang JL, Tien HF. Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial. Biol Blood Marrow Transplant 2018;24:2310-5. [PMID: 30026110 DOI: 10.1016/j.bbmt.2018.07.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Singh L, Indermun S, Govender M, Kumar P, du Toit LC, Choonara YE, Pillay V. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. Viruses 2018;10:E267. [PMID: 29772748 DOI: 10.3390/v10050267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]